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Pilot Trial on Determinants of Progenitor Cell Recruitment
to the Infarcted Human Myocardium
Volker Schächinger, MD*; Alexandra Aicher, MD*; Natascha Döbert, MD; Rainer Röver, BSc;
Jürgen Diener, MD; Stephan Fichtlscherer, MD; Birgit Assmus, MD; Florian H. Seeger, MD;
Christian Menzel, MD; Winfried Brenner, MD; Stefanie Dimmeler, PhD; Andreas M. Zeiher, MD
Background—Clinical trials indicate a beneficial effect of intracoronary infusion of progenitor cells on myocardial
function in patients with ischemic heart disease. The extent and potential determinants of proangiogenic progenitor cell
homing into the damaged myocardium after intracoronary infusion and the underlying mechanisms are still unknown.
Method and Results—Circulating proangiogenic progenitor cells isolated from peripheral blood and cultivated for 3 days
were labeled with radioactive indium oxine (111In-oxine). Radiolabeled proangiogenic progenitor cells (7.63.0 MBq,
meanSD) were administered to patients with previous myocardial infarction and a revascularized infarct vessel at
various stages after infarction (5 days to 17 years). Viability of the infarcted myocardium was determined by
18F-fluorodeoxyglucose–positron emission tomography and microcirculatory function by intracoronary Doppler mea-
surements. One hour after application of progenitor cells, a mean of 6.94.7% (range, 1% to 19%; n17) of total
radioactivity was detected in the heart, which declined to 21% after 3 to 4 days. Average activity within the first 24
hours was highest among patients with acute myocardial infarction (14 days; 6.32.9%; n8) and progressively
decreased in patients treated in an intermediate phase (14 days to 1 year; 4.53.2%; n4) or a chronic stage (infarct
age 1 year; 2.51.6%; n5). Low viability of the infarcted myocardium and reduced coronary flow reserve were
significant (P0.05) predictors of proangiogenic progenitor cell homing.
Conclusions—In patients after myocardial infarction undergoing intracoronary infusion of 111In-oxine–labeled proangio-
genic progenitor cells, a substantial amount of radioactivity is detected for several days in the heart, indicating homing
of progenitor cells to the myocardium. The amount of proangiogenic progenitor cells retained in the heart decreased
progressively with time after the acute myocardial infarction. Proangiogenic progenitor cells preferentially home to
extensive acute myocardial infarcts characterized by low viability and reduced coronary flow reserve. (Circulation.
2008;118:1425-1432.)
Key Words: heart failure  microcirculation  myocardial infarction  nuclear medicine  stem cells
Cell therapy is a promising option to treat ischemicdiseases. Several cell types, including embryonic stem
cells, skeletal myoblasts, bone marrow–derived cells, circu-
lating progenitor cells (CPCs), and tissue-resident cardiac
stem cells, have been used in experimental studies to improve
recovery after acute ischemia and to repair chronically
damaged myocardium.1 In the clinical setting, patients with
acute and chronic myocardial infarction were treated with
bone marrow–derived cells or blood-derived CPCs, whereas
skeletal myoblasts were injected in chronic heart failure
patients to improve heart function.1 The clinical trials in
patients with acute myocardial infarction (AMI) and chronic
ischemic heart disease were recently assessed in a meta-anal-
ysis of all studies currently available showing that cell
therapy is associated with modest improvements in physio-
logical and anatomic parameters above and beyond conven-
tional therapy.2 In line with this, recent evaluation of the
clinical follow-up of the Reinfusion of Enriched Progenitor
Cells and Infarct Remodeling in Acute Myocardial Infarction
(REPAIR-AMI) trial revealed a significant reduction in
adverse clinical end points, setting the stage for future testing
of clinical efficacy of cell therapy in AMI.3,4
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Despite these promising clinical studies, several questions
about cell therapy remain unanswered, including the inten-
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sively discussed question about the mechanism by which cell
therapy exhibits its beneficial effects. Direct physical contri-
bution by differentiation into cardiac myocytes (cardiac
regeneration) or the formation of new vessels (vasculogen-
esis) and paracrine activities of the transplanted cells have
been considered to mediate the functional recovery of the
heart after cell infusion.5 Of note, all of these mechanisms,
even the short-term paracrine activities, depend on an initial
homing and subsequent engraftment to the target tissue.
Therefore, experimental and clinical studies attempt to inves-
tigate the initial homing by in vivo imaging. Noninvasive
imaging has been performed by direct labeling with gamma-
emitting radionuclides for gamma camera6 or single-photon
emission computed tomography imaging,7,8 by using positron
emitters such as [18F]fluorodeoxyglucose (FDG) for positron
emission tomography (PET),9,10 or by labeling of cells with
iron particles for magnetic resonance imaging.11–14 All strat-
egies were used successfully in experimental models with
some limitations (for review, see Beeres et al15). Clinically,
labeling of bone marrow–derived cells or isolated CD133
cells with the radiopharmaceutical 111In-oxine was performed
in several case reports in patients with AMI or chronic
myocardial infarction.16,17 Hofmann et al18 infused bone
marrow–derived cells or CD34 cells labeled with the PET
tracer FDG into 3 patients with AMI. All experimental and
clinical studies demonstrated a relatively low (ranging from
2% to 11%) acute accumulation of 111In activity in the heart
in patients treated with bone marrow–derived cells or
CD133 cells. Only purified FDG-labeled CD34 cells were
shown to home more efficiently into the heart (14% to
39%).18 However, the reasons for the individual variation of
cell homing are still unclear.
Here, we investigated the homing of intracoronary infused
111In-oxine–labeled ex vivo cultured peripheral blood-derived
CPCs in 17 patients with AMI and chronic myocardial
infarction to determine potential predictors of homing. Cul-
tivated circulating cells were chosen because of their lower
sensitivity to irradiation-induced dysfunction and cell
death.6,19
Methods
Patients
Twenty post–myocardial infarction patients were recruited between
May 2005 and December 2006 into this single-center study. In 17
patients with an open infarct-related artery (either after stent implan-
tation or bypass grafting), 111In-oxine–labeled progenitor cells were
infused, and subsequent imaging was performed. Infarct age ranged
from 5 days to 17 years (8 patients with AMI within the last 14 days
[14 days], 4 patients in an intermediate phase of 14 days to 1
year, and 5 patients with chronic ischemic heart disease [infarct age
1 year]). One patient with AMI was excluded because no gamma
camera imaging could be performed. In 2 patients with an occluded
infarct-related artery, labeled progenitor cells were infused into a
noninfarcted vessel, providing angiographically visible collaterals to
the occluded infarct vessel.
In brief, exclusion criteria were defined as evidence for malignant
disease, infectious or inflammatory disease, active bleeding, stroke
within 2 years, surgery or trauma within 2 months, uncontrolled
hypertension, renal or liver dysfunction, thrombocytopenia, or ane-
mia. The ethics review board of the Hospital of the Johann Wolfgang
Goethe University of Frankfurt, Germany, and the Federal Agency
for Radiation Safety (Bundesamt für Strahlenschutz), Germany,
approved the protocol, and the study was conducted in accordance
with the Declaration of Helsinki. Written informed consent was
obtained from each patient.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
CPC Preparation and Labeling
Venous blood (250 mL) was collected, and mononuclear cells were
purified and ex vivo cultured for 3 days as previously described by
Assmus et al.20 Briefly, adherent cells were detached with
0.5 mmol/L EDTA, and 106 CPCs were resuspended in a final
volume of 5 mL growth factor and serum-free X-VIVO-10 medium
(Biowhittaker, Verviers, Belgium) to be labeled with 25 MBq
111In-oxine (half-life, 2.8 days;  energy, 171 keV, 245 keV, 37
MBq/mL, Tyco Healthcare, Neustadt, Germany) according to the
manufacturer’s instructions with regard to pH adjustment and were
incubated for 60 minutes at 37°C (see Aicher et al6). Cells were
washed twice with PBS. Then, labeled CPCs were resuspended in
serum-free X-VIVO-10 medium and stored in a syringe in a total
volume of 8 mL. Labeling efficacy was measured with a dose
calibrator, and cell viability was assessed by trypan blue exclusion.19
The remaining unlabeled CPCs also were washed, resuspended in
serum-free X-VIVO-10 medium, and stored in a separate syringe
(with a total volume of 8 mL).
Infusion Protocol
CPCs were administered using the previously described stop flow
technique.20,21 In brief, after arterial puncture, patients who were
pretreated with aspirin and clopidogrel were given 7500 to 10 000 U
heparin. Patients received both 106 radiolabeled CPCs and subse-
quently the remaining unlabeled CPC. First, 4 mL labeled CPC was
infused via an over-the-wire balloon catheter advanced into the
coronary artery supplying the infarct territory. Then, the balloon was
inflated with low pressure to completely block blood flow for 3
minutes. After 3 minutes of reflow, the procedure was repeated.
Subsequently, unlabeled CPCs were infused in 2 portions, 4 mL
each, in the same way.
Doppler Measurements
Before CPC administration, coronary blood flow velocity was
assessed via an intracoronary Doppler wire (Flowire, Cardiometrics
Inc, Mountain View, Calif) as previously described.22 In brief, the
Doppler wire was advanced to the infarct artery and a noninfarcted,
nonstenosed reference vessel (if available), and coronary flow was
assessed at baseline and during maximal hyperemia induced by
intracoronary adenosine infusion via the guiding catheter (2.4
mg/min).
Average peak velocity was recorded at baseline and during
maximal hyperemia induced by adenosine, and coronary flow
reserve (CFR) in each vessel was calculated as the ratio between
adenosine-induced and basal average peak velocities. Relative
CFR was calculated by dividing infarct vessel CFR by reference
vessel CFR.
FDG-PET Studies
FDG-PET was performed with a whole-body PET scanner (ECAT
EXACT 47, Siemens CTI, Malvern, Pa) as previously described.20
Standardized quantitative analysis of myocardial viability was per-
formed with FDG-PET bull’s-eye views and by calculating the mean
signal intensity in 17 myocardial segments. Segments supplied by
the infarct area were defined according to the coronary anatomy.23
Finally, mean PET activity of all segments targeted by the artery
supplying the infarct area was calculated.
Monitoring of 111In Activity
Whole-body scintigraphy with a large-field double-head gamma
camera equipped with high-resolution middle-energy collimators
was used to detect radioactivity of infused 111In-oxine–labeled CPC.
Gamma camera studies using the same region of interest were
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performed at 3 time points: 1 hour, 24 hours, and 3 or 4 days after
intracoronary infusion of labeled CPCs. 111In activity was monitored
for the whole body and the heart, lung, liver, spleen, head, and bone
marrow (region of interest within the os sacrum). 111In activity for
these organs is corrected for decay and background activity and
given as the percentage of total radioactivity. Average 111In activity
within the first 24 hours was calculated as the area under the curve
of 111In activity divided by the actual time difference between
intracoronary infusion and the 24-hour measurement.
Statistical Analysis
Continuous variables are presented as meanSD (if not stated
otherwise). In this descriptive pilot trial, no statistical analyses on
subgroup comparisons were performed. Correlation of continuous
data was performed by Spearman’s correlation coefficient. Statistical
significance was assumed if values of P0.05. All reported proba-
bility values are 2 sided. Statistical analyses were performed with
SPSS (Version 14.0, SPSS Inc, Chicago, Ill).
Results
Patient characteristics are summarized in the Table. A total
number of 156.2106 progenitor cells, of which 10%
were labeled, were infused into the coronary artery of 17
patients with an over-the-wire balloon catheter. The average
111In activity of infused labeled CPCs was 7.63.0 MBq, and
cell viability was 9060.5%. 111In activity in the heart was
highest 1 hour after application of CPCs (6.94.7%; range,
1% to 19%) and progressively and substantially declined to
21% after 3 to 4 days (Figures 1 and 2). Throughout the
observation period of 3 to 4 days after intracoronary infusion
of CPCs, a continuous level of 111In activity was detected in
the liver and spleen, whereas 111In activity was highest
immediately after infusion and progressively diminished in
the lung and heart during the next days (Figure 2). Uptake in
the bone marrow was low in all patients (Figure 2).
To determine whether infusion of CPCs into the collateral
supplying artery is suitable to provide CPCs to infarcted areas
with completely occluded infarct-related arteries, 2 additional
patients received CPCs via the collateral supplying artery (see
the Figure in the online-only Data Supplement). Average
radioactivity within the first 24 hours in the heart was 3.0% in
one of these patients and 9.0% in the other. However, gamma
camera imaging suggested that significant 111In uptake was
confined to the territory of the infused vessel, but no 111In
uptake was observed in the target area supplied by the
collaterals via retrograde filling of the occluded infarct-
related artery.
Predictors of CPC Homing
It is known that acute ischemia enhances the expression of
chemoattractants and cytokines mediating homing of CPCs in
experimental models. To determine whether acute ischemia
indeed contributes to an augmented uptake of radioactively
labeled cells, patients were stratified according to the interval
Table. Patient Characteristics
Days/Years
Since MI
Infarct
Vessel Age, y CABG Gender Hypertension Diabetes
Smoking
Status
Smoking,
Pack-y
Ejection
Fraction
by
QLVA, %
111In Activity
at
Incubation,
MBq
111In
Activity–Labeled
Cells, MBq
Viability of
Labeled
Cells, %
Total
Cells,
106
PET
Viability
in Target
Segments
Infusion in open
infarct vessel
(n17)
5 d LAD 64    Female Yes    Current 15 57 25.3 5.7 95 11 58
5 d LAD 67    Female Yes       0 57 22.6 10.7 78 22 62
7 d LAD 64    Male Yes NIDDM Former 100 51 28.4 3.3 93 12 ND
8 d LAD 60    Female          0 50 25.2 6.3 89 14 56
8 d RCA 61    Female Yes    Former 18 44 26.9 10.7 90 19 63
10 d LAD 64    Male       Former 40 53 24.0 8.1 100 11 67
11 d LAD 51    Male Yes    Current 45 64 31.5 10.3 83 15 56
14 d LAD 50    Female       Current 33 51 25.4 8.7 100 12 46
36 d LCA 53    Male       Former 15 53 24.2 6.9 81 15 78
45 d LCx 58    Male       Current 35 41 25.8 6.4 82 12 77
100 d LAD 67    Male Yes       0 50 29.7 5.6 89 9 36
278 d LAD 58    Male       Former 70 ND 27.5 7.8 89 17 38
3.5 y LAD 53    Male Yes IDDM Former 45 49 25.4 15.0 100 35 56
4.8 y RCA 67    Male          0 46 24.3 2.4 88 8 61
11.6 y LAD 61 Yes Male Yes    Former 45 28 25.0 6.1 88 16 28
12.9 y LAD 65 Yes Female    IDDM Former 40 38 25.3 6.2 89 14 53
17.2 y LCx 60    Male Yes    Former 35 43 24.4 8.9 91 17 63
Infusion in
collaterals
(n2)
227 d LAD* 68    Male Yes       0 29 25.4 5.7 ND 8 ND
Silent LAD* 47 Yes Male Yes NIDDM Former 100 59 17.5 4.5 100 10 70
CABG indicates coronary artery bypass grafting; QLVA, quantitative coronary angiography with area-length method; LAD, left anterior descending artery; NIDDM,
non–insulin-dependent diabetes mellitus; ND, not done; RCA, right coronary artery; LCx, left circumflex artery; and IDDM, insulin-dependent diabetes mellitus.
Characteristics are in chronological order with respect to timing after myocardial infarction.
*Cells were infused into the RCA.
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between cell administration and time point of myocardial
infarction. Figure 3A illustrates 111In activity in the heart of
each individual patient along the time course separated into
the 3 groups of infarct age. Average 111In activity in the heart
within the first 24 hours was highest in patients receiving
CPC infusion within 14 days (14 days) after an AMI
(6.32.9%), intermediate in patients receiving cells 14
days to 1 year after AMI (4.53.2%), and lowest in patients
with healed infarcts that occurred 1 year before cell
administration (2.51.6%). Thus, 111In uptake in the heart,
expressed as an average of the measures within the first 24
hours, demonstrated a significant inverse correlation with the
temporal interval between AMI and cell administration
(r0.59, P0.012; n17) (Figure 3B), suggesting that the
infarct age determines both uptake and retention of intracoro-
nary infused radiolabeled cells. This association also was
preserved when only patients with old infarcts (1 year)
were analyzed. In contrast, no association was found between
111In activity and infarct size as measured by the number of
segments supplied by the infarct artery.
Although homing of labeled cells was significantly higher
in patients receiving progenitor cells within 1 year after AMI,
Figure 3A illustrates the large variability of individual uptake
of radioactivity in this patient population. Therefore, we
Figure 1. Example of 111In uptake in patient after
an anterior AMI (cell administration 5 days after
acute PCI). A, Coronary angiogram before cell
infusion. Arrows denote site of cell infusion. B, Left
ventricular (LV) angiogram. C, FDG-PET imaging.
Dark scale indicates low viability. D, Imaging of
111In distribution with gamma camera at 1 hour, 24
hours, and 4 days after infusion of 111In-oxine–la-
beled CPCs. Anterior and posterior whole-body
scans were acquired. The inserts show the heart
at a higher magnification.
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investigated the influence of viability of the infarcted myo-
cardium as a measure of severity of myocardial damage on
average 111In uptake in the heart. FDG-PET–determined
viability of the infarcted myocardium was inversely corre-
lated with a higher average 111In activity within the infarct
territory (Figure 4). In contrast, in patients with healed
myocardial infarction (1 year old), no correlation of CPC
homing was found as measured by average 111In activity and
FDG-PET–derived myocardial viability.
When cells are applied via the coronary system, CPC
adhesion and extravasation are required for homing and
eventual tissue engraftment. To obtain insight into the poten-
tial role of the integrity of vascular function, coronary
microcirculatory function was assessed after adenosine infu-
sion in 11 patients with myocardial infarctions 1 year old
before infusion of 111In-oxine–labeled cells. Average 111In
activity after CPC infusion was highest in patients with
impaired coronary microcirculatory function and declined
with increasing CFR (Figure 5A). These results were con-
firmed if CFR was normalized to a noninfarcted reference
vessel (Figure 5B).
Discussion
The results of the present descriptive pilot study demonstrate
that 3 critical factors are likely to determine the uptake of
labeled CPCs in the patient’s heart after intracoronary admin-
istration: infarct age, the extent of tissue damage, and the
integrity of the coronary microcirculation. The data demon-
strating a reduced homing of progenitor cells in chronic
compared with AMI are well rationalized by the higher
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Figure 3. A, Individual time course of 111In
activity in the heart according to infarct
stage. B, Correlation between average 111In
uptake in the heart and infarct age (loga-
rithmic scale). CHD indicates coronary
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Figure 4. Correlation between FDG-PET activity, which repre-
sents FDG incorporation into viable tissue, and average 111In
uptake within the first 24 hours for patients with infarct 1 year old.
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expression and release of chemoattracting cytokines during
acute ischemia. AMI has experimentally been demonstrated
to increase cytokines such as stromal cell-derived factor 1
(SDF-1), which enhances adhesion and transmigration of
proangiogenic CPCs and hematopoietic stem cells.24,25 Re-
cent studies additionally suggested that SDF-1 not only acts
as a chemoattractant factor but also retains proangiogenic
cells in the perivascular region.26 Likewise, SDF-1 serum
levels are elevated in patients after AMI.27 In addition,
hypoxia and inflammation as induced by myocardial infarc-
tion augment vascular endothelial growth factor and
interleukin-8, both of which can attract subsets of progenitor
cells.28,29 In human ischemic limb muscle, vascular endothe-
lial growth factor, SDF-1, and CXCR4 expression was shown
to be significantly augmented compared with nonischemic
controls.30 Interestingly, when those investigators determined
the expression of the cytokines in patients with chronic
ischemia, the levels of vascular endothelial growth factor,
SDF-1, and the SDF-1 receptor CXCR4 were significantly
reduced below the levels of the nonischemic control mus-
cles,30 indicating a severe reduction in these chemoattractants
and cytokines in chronic ischemia. The finding that the extent
of damaged tissue as assessed by FDG-PET measurement
also correlated with increased CPC homing in AMI further
supports the hypothesis that inflammatory processes and
possibly necrotic tissue-derived factors act as chemoattrac-
tants in vivo.31 In addition, it is well established that progen-
itor cells derived from patients with chronic ischemic heart
failure are functionally impaired.32 Indeed, although the small
sample size of the present study precluded a more in-depth
analysis, it is most likely that intracoronary infused progen-
itor cells derived from patients with chronic ischemic heart
failure are less responsive to chemoattractants.
An impaired CFR measured directly before cell infusion
was associated with an increased uptake of radiolabeled cells.
An impairment in coronary vasodilator function after AMI is,
among other reasons, associated with systemic inflammation
and local leukocyte plugging,33,34 both indicating an inflamed
and activated endothelium. Cytokine-mediated activation of
the endothelium increases adhesion molecules, which act as
binding partners to integrins expressed on the surface of
progenitor cells. For example, 2 integrins are highly ex-
pressed on CPCs35 and bind to intercellular adhesion
molecule-1, which is increased in dysfunctional endotheli-
um.36 Although a cause-effect relationship obviously cannot
be established by the present study, the importance of the
ability of damaged myocardium to attract CPCs is under-
scored by a recent trial demonstrating that intracoronary
infusion of bone marrow–derived progenitor cells normalizes
impaired postinfarction CFR.37
The biodistribution of radiolabeled cells and the extent of
incorporation detected in the present study are consistent with
previous case reports. With a similar labeling protocol, the
111In radioactivity in the heart was reported to be 2.6%, 4.9%,
and 11% in 3 patients treated with bone marrow–derived
mononuclear cells 4 to 7 days after AMI.16 Slightly lower
incorporation (1.3% to 2.6%) was described in 3 patients who
received bone marrow–derived cells labeled with FDG.18 It
has been discussed whether a different mode of application
may further enhance cell homing. Although to the best of our
knowledge no information is available in the clinical setting,
experimental studies demonstrated a slightly higher initial
engraftment after intramuscular delivery of cells.8 In this
study, the efficiency of interstitial retrograde coronary venous
delivery was similar to that of coronary delivery.8 When we
used collateral arteries to deliver cells to the nonviable
infarcted tissue, migration through the collaterals appeared to
be hampered. Thus, further studies should evaluate whether
distinct delivery strategies are useful for improving the poor
engraftment in humans. Alternatively (or additionally), aug-
mentation of cell engraftment may be achieved by novel
molecular strategies to increase homing and survival of the
cells, particularly in chronic disease states. Experimental data
provide promising results by preactivating the tissue by
low-energy shock waves or by using biomaterials to release
cytokines, thereby promoting engraftment and survival.38,39
The present descriptive pilot trial using radioactive label-
ing is limited in sample size; therefore, no statistical compar-
isons of subgroups can be applied. A further limitation of the
present study, shared with all clinically applicable noninva-
sive imaging techniques at present, is that we cannot ensure
that the detected radioactivity equals living and functionally
active cells. Although our preclinical studies demonstrated
that free 111In radioactivity is not taken up by infarcted
hearts,6 we cannot exclude that 111In-labeled CPCs are phago-
cytosed by inflammatory cells. Moreover, radioactivity can
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Figure 5. CFR and average 111In uptake. A, CFR in target (infu-
sion) vessel. B, Relative CFR.
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be released by the labeled cells. However, this nonspecific
release should most likely be similar in acute and chronic
conditions and therefore may not be the cause of the signif-
icantly impaired cardiac uptake in chronic disease. Finally,
the short-term monitoring of cells does not give insights into
the long-term engraftment and function of the applied cells.
However, without an initial homing, infused cells cannot
exert either paracrine or regenerating activity. Therefore, the
present study, with all its limitations, provides a basis for
evaluating cell therapy–enhancing strategies in the future.
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CLINICAL PERSPECTIVE
This study investigates homing of radioactively labeled circulating progenitor cells into the infarct territory after
intracoronary infusion into the infarct-related artery in patients after myocardial infarction. The salient findings are that the
temporal proximity to the ischemic event, the extent of myocardial necrosis, and the magnitude of functional impairment
of the coronary microcirculation are individually likely to determine an increased uptake and short-term retention of
progenitor cells administered into the infarct-related coronary artery. These findings may indicate that the inflammatory
processes ignited by the infarcted and necrotic myocardium may play a major role in the recruitment of progenitor cells
into the ischemic tissue. Consequently, when the inflammatory activation of the coronary vasculature subsides during
infarct healing and scar formation, recruitment and homing of intravascularly administered progenitor cells may be
reduced.
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